Welcome to our dedicated page for Quoin Pharmaceuticals news (Ticker: QNRX), a resource for investors and traders seeking the latest updates and insights on Quoin Pharmaceuticals stock.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) is a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, with a primary emphasis on severe genetic skin disorders and related conditions. The QNRX news feed on Stock Titan aggregates company press releases and market-moving updates that shed light on the progress of its clinical pipeline, regulatory interactions and financing activities.
Investors following QNRX news can see detailed updates on the development of the company’s lead asset, QRX003, a topical lotion in late-stage pivotal trials for Netherton Syndrome. Quoin regularly reports clinical data from investigator-led pediatric studies and pivotal programs, describing changes in skin condition, pruritus, sleep disturbance and use of concomitant medications in Netherton Syndrome patients. News items also cover initial positive data in Peeling Skin Syndrome and the potential versatility of QRX003 across multiple rare skin diseases.
Regulatory and designation milestones are another key component of Quoin’s news flow. The company has announced Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency for QRX003 in Netherton Syndrome, as well as Rare Pediatric Disease Designation in the United States. These updates provide context on potential market exclusivity and incentives that may affect the long-term outlook for the program.
Quoin’s news also highlights broader corporate developments, including private placement financings with healthcare-focused institutional investors, adoption of equity incentive plans, leadership changes such as the appointment of a new chief financial officer and shareholder meeting outcomes. In addition, the company issues regular communications about its NETHERTON NOW awareness campaign, releasing video episodes that feature patients, advocates and experts discussing the burden of Netherton Syndrome. For readers tracking QNRX, this news stream offers an ongoing view into clinical progress, regulatory events, capital formation and patient advocacy efforts related to Quoin’s rare disease focus.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced the dosing of the first patient in its open-label clinical trial for QRX003 targeting Netherton Syndrome. This study evaluates the safety and efficacy of QRX003 in patients receiving off-label systemic therapy over a twelve-week period. Various clinical endpoints will be assessed, including Investigator Global Assessment and Patient Global Assessment. Concurrently, Quoin is also running a double-blind vehicle-controlled study for QRX003. The company expects to report topline data from this trial in the latter half of 2023. These efforts position QRX003 as a potential standard of care for Netherton patients.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced the dosing of the first patient in a double-blinded clinical trial for QRX003 targeting Netherton Syndrome. The company initiated a second trial assessing QRX003 in patients on off-label therapy, cleared by the FDA. Quoin partnered with Queensland University of Technology to advance dermatological research, aiming for clinical testing by late 2023. Financially, Quoin reported a net loss of approximately $9.4 million for 2022, with $12.9 million in cash. A recent public offering raised $6 million, extending the cash runway into the second half of 2024, crucial for development efforts.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) will release its 2022 fourth quarter and year-end financial results on March 8, 2023, after market close. A conference call and webcast are scheduled for March 9, 2023, at 8:30 AM ET to discuss these results. Investors can join the call by calling 1-877-270-2148 domestically or 1-412-902-6510 internationally. Quoin focuses on developing therapeutic products for rare and orphan diseases, with a pipeline including treatments for conditions like Netherton Syndrome and Epidermolysis Bullosa. For more details, visit their official website.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced the pricing of a public offering featuring 24,750,000,000 ordinary shares priced at $1.00 per American Depositary Share (ADS) and pre-funded warrants for 10,250,000,000 ordinary shares at $0.9999 each. The offering aims to raise approximately $7.0 million before expenses, expected to close on February 24, 2023. The company will utilize the net proceeds for general corporate purposes. Additionally, Quoin will amend outstanding warrants from a previous offering, reducing their exercise price from $5.00 to $1.10 per ADS, set to expire on February 24, 2028.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that its second clinical study for QRX003, a potential treatment for Netherton Syndrome, has been cleared by the FDA to initiate testing. The first patient has been dosed in the ongoing trial, which assesses the safety and efficacy of QRX003 versus a vehicle lotion over 12 weeks. All six target clinical sites are expected to be fully operational by the end of the year, accelerating patient recruitment for both studies. The company aims to address the unmet needs of Netherton patients, a rare and sometimes fatal disease.
Quoin Pharmaceuticals (QNRX) has recently completed a public offering, raising $16.8 million in gross proceeds. The majority of clinical sites for evaluating QRX003 in Netherton Syndrome are now open, with plans for a second trial for patients on off-label treatment. An international partnership with Endo Ventures for commercialization in Canada has been signed, extending coverage to 60 countries. As of Q3 2022, Quoin reported a net loss of $3 million and operating expenses of $2.3 million, ending the quarter with $15.2 million in cash and marketable securities.
FAQ
What is the current stock price of Quoin Pharmaceuticals (QNRX)?
What is the market cap of Quoin Pharmaceuticals (QNRX)?
